BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
1. VOXZOGO shows anatomical spinal improvements in children with achondroplasia. 2. Significant growth after puberty onset noted in treated teenagers. 3. VOXZOGO is the only approved treatment with spinal morphology benefits. 4. BioMarin presenting pivotal data on ENPP1 deficiency treatment BMN 401. 5. Continued efficacy of VOXZOGO reinforces its importance in pediatric care.